Recently, Zhu et al. [107] synthesized 131I-labeled Nb109 (a nanobody targeting PD-L1) to inhibit tumor growth in NSCLC cells without toxic effects and described the therapeutic efficacy of 131I-Nb109 with in vitro and in vivo studies. Here, CD274 is linked to neoplasm.